Search
Selected Filter
Displaying 1–10 of 24 news results
-
Foundation Fighting Blindness Appoints Judy Taylor Vice President, Development
Ms. Taylor brings over twenty-five years of successful non-profit experience, including executive-level positions, to Foundation
-
Sustained Suppression of VEGF: Looking Forward and Looking Back
The results of the LADDER trial demonstrate a major step forward but introduce many questions.
-
Gene Therapy Trials for Wet Age-Related Macular Degeneration
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Bipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
-
Foundation Fighting Blindness InSights Forum Call
The Foundation Fighting Blindness is pleased to provide an audio recording and full transcripts of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on March 22, 2019.
-
Foundation Fighting Blindness Announces Staffing Changes to Enhance Strategic Direction
The Foundation announces several staffing changes with a focus on new strategies to increase awareness and engagement with the community.
-
The Foundation Fighting Blindness and Dr. H. James & Carole Free Collaborate to Combat AMD
Age-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years of age in developed countries.
-
Sixth Annual Retinal Cell and Gene Therapy Innovation Summit
The Foundation Fighting Blindness (FFB), a national nonprofit focused on funding cutting-edge retinal disease research, and the Casey Eye Institute at Oregon Health & Science University will co-host the sixth annual Retinal Cell and Gene Therapy Innovation Summit in Vancouver, British Columbia, on Friday, April 26, 2019. The summit takes place just prior to the 2019 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
More than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
